These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29299126)

  • 1. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
    Juengel E; Najafi R; Rutz J; Maxeiner S; Makarevic J; Roos F; Tsaur I; Haferkamp A; Blaheta RA
    Oncotarget; 2017 Dec; 8(66):110016-110028. PubMed ID: 29299126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro.
    Makarević J; Rutz J; Juengel E; Maxeiner S; Tsaur I; Chun FK; Bereiter-Hahn J; Blaheta RA
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.
    Makarević J; Rutz J; Juengel E; Maxeiner S; Mani J; Vallo S; Tsaur I; Roos F; Chun FK; Blaheta RA
    Cells; 2018 Sep; 7(9):. PubMed ID: 30200497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
    Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
    Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
    Juengel E; Nowaz S; Makarevi J; Natsheh I; Werner I; Nelson K; Reiter M; Tsaur I; Mani J; Harder S; Bartsch G; Haferkamp A; Blaheta RA
    Mol Cancer; 2014 Jun; 13():152. PubMed ID: 24935000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro.
    Juengel E; Natsheh I; Najafi R; Rutz J; Tsaur I; Haferkamp A; Chun FK; Blaheta RA
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
    Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
    Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2.
    Makarević J; Rutz J; Juengel E; Kaulfuss S; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    PLoS One; 2014; 9(8):e105590. PubMed ID: 25136960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
    Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
    BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
    Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Clin Exp Metastasis; 2011 Jun; 28(5):479-91. PubMed ID: 21452015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
    Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
    Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
    Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Blaheta RA
    J Cell Mol Med; 2009 Aug; 13(8B):2376-2385. PubMed ID: 18657224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro.
    Xie H; Rutz J; Maxeiner S; Grein T; Thomas A; Juengel E; Chun FK; Cinatl J; Haferkamp A; Tsaur I; Blaheta RA
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro.
    Strey CW; Schamell L; Oppermann E; Haferkamp A; Bechstein WO; Blaheta RA
    Exp Ther Med; 2011 Mar; 2(2):301-307. PubMed ID: 22977502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.